Hepatitis C virus (HCV) infects over 170 million people worldwide, and is the main cause of cirrhosis, hepatocellular carcinoma and liver transplant. There are 7 HCV genotypes, and genotype 1 accounts for 75% of cases. The virus persists in the liver of 85% of those infected and, prior to July 2011, the Standard of Care (SoC) for genotype 1 was pegylated-interferon (PEG-interferon) and ribavirin administered over 48 weeks. The SoC had a cure rate of 50-55% yet was associated with significant side effects including hematological, flu-like symptoms, and cognitive impairment.
Since July 2011, cure rates of up to 75% have been achieved by combining Specifically Targeted Antiviral Therapy (STAT-C) with PEG-interferon and ribavirin, also administered over long periods. However, a significant percentage of patients has either withdrawn due to side effects, or not responded.
Tacere has designed a ddRNAi –based multi-cassette vector called TT-034 which targets 3 parts of the HCV genome in a single intravenous dose. TT-034 has achieved over 90% transfection of liver cells and, by targeting 3 separate, well-conserved regions of HCV simultaneously, it prevents generation of drug-resistant mutants, a major problem in the treatment of Hepatitis C. The targeted regions of HCV are also conserved across all genotypes, so TT-034 has likely application to all HCV-caused conditions. Read more about TT-034 here.
Tacere is advancing TT-034 to the clinic via these important steps:
TT-034 moves closer to the clinic
Watch the interview with SVP of
Research & Development, Dr David Suhy.
Our biological drugs target and silence unwanted genes, safely and with lasting effect. More
TT-034, our drug to treat Hepatitis C with a single dose, is poised to commence clinical trial. More